These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38346600)

  • 1. Ethanol-based solubility-enabling oral drug formulation development: Accounting for the solubility-permeability interplay.
    Fine-Shamir N; Dahan A
    Int J Pharm; 2024 Mar; 653():123893. PubMed ID: 38346600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
    Fine-Shamir N; Dahan A
    Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
    Beig A; Miller JM; Lindley D; Dahan A
    Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation.
    Fine-Shamir N; Beig A; Miller JM; Dahan A
    Int J Pharm; 2020 May; 582():119307. PubMed ID: 32276090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
    Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
    Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
    Dahan A; Beig A; Lindley D; Miller JM
    Adv Drug Deliv Rev; 2016 Jun; 101():99-107. PubMed ID: 27129443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
    Beig A; Miller JM; Dahan A
    Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active intestinal drug absorption and the solubility-permeability interplay.
    Porat D; Dahan A
    Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.
    Dahan A; Miller JM
    AAPS J; 2012 Jun; 14(2):244-51. PubMed ID: 22391790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
    Beig A; Agbaria R; Dahan A
    PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
    Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
    Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development.
    Fine-Shamir N; Dahan A
    Expert Opin Drug Deliv; 2024; 21(1):13-29. PubMed ID: 38124383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM; Beig A; Carr RA; Spence JK; Dahan A
    Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems.
    Fine-Shamir N; Beig A; Dahan A
    Int J Pharm; 2021 Mar; 597():120295. PubMed ID: 33497706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin.
    Kristin F; René H; Boontida M; Buraphacheep JV; Maximilian A; Johanna M; Peter L
    Eur J Pharm Sci; 2017 Apr; 101():211-219. PubMed ID: 28179133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
    Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
    J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of combining supersaturating and solubilizing formulations - Is two better than one?
    Alvebratt C; Karlén F; Åhlén M; Edueng K; Dubbelboer I; Bergström CAS
    Int J Pharm; 2024 Sep; 663():124437. PubMed ID: 39002818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.